Fig. 3.
Fig. 3. OVA-specific AFCs in spleen, nasal tract, lung, and intestinal lamina propria. / Groups of 5 C57BL/6 mice were nasally immunized on days 0, 7, and 14 with 75 μg OVA and 0.0 (■)or 1.0 μg MIP-1α (▨) or MIP-1β (▪) in PBS. Levels of OVA-specific AFCs present in spleen, intestinal lamina propria, and respiratory tracts, including associated lymphoid tissue, were determined by ELISPOT analysis 7 days after the last immunization. AFCs below detectable levels (fewer than 10 AFCs per 106 lymphocytes) are designated BD. The data presented are the mean AFCs ± SEMs, in duplicate cultures, of 3 separate experiments. Asterisks indicate statistically significant differences (P < .05) from AFCs of mice immunized with OVA alone.

OVA-specific AFCs in spleen, nasal tract, lung, and intestinal lamina propria.

Groups of 5 C57BL/6 mice were nasally immunized on days 0, 7, and 14 with 75 μg OVA and 0.0 (■)or 1.0 μg MIP-1α (▨) or MIP-1β (▪) in PBS. Levels of OVA-specific AFCs present in spleen, intestinal lamina propria, and respiratory tracts, including associated lymphoid tissue, were determined by ELISPOT analysis 7 days after the last immunization. AFCs below detectable levels (fewer than 10 AFCs per 106 lymphocytes) are designated BD. The data presented are the mean AFCs ± SEMs, in duplicate cultures, of 3 separate experiments. Asterisks indicate statistically significant differences (P < .05) from AFCs of mice immunized with OVA alone.

Close Modal

or Create an Account

Close Modal
Close Modal